Inventor
CRAWFORD ALISON
US12 patents
Patents
12 patentsUS10772972B2Sep 15, 2020
Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
REGENERON PHARMA44 citations97
US10738130B2Aug 11, 2020
Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereof
REGENERON PHARMA50 citations97
US10179819B2Jan 15, 2019
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
REGENERON PHARMA25 citations93
US11155633B2Oct 26, 2021
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
REGENERON PHARMA9 citations85
US11453721B2Sep 27, 2022
Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
REGENERON PHARMA10 citations84
US11485793B2Nov 1, 2022
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA4 citations83
US10941208B2Mar 9, 2021
Anti-MUC16 antibodies
REGENERON PHARMA6 citations83
US11633501B2Apr 25, 2023
Anti-STEAP2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind STEAP2 and CD3, and uses thereof
REGENERON PHARMA3 citations72
US11254752B2Feb 22, 2022
Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies
REGENERON PHARMA2 citations72
US12344677B2Jul 1, 2025
Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
REGENERON PHARMA0 citations62
US12570764B2Mar 10, 2026
Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereof
REGENERON PHARMA0 citations61
US12091460B2Sep 17, 2024
Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
REGENERON PHARMA0 citations55